CORONA Remedies (CORONA) Q4 24/25 earnings summary

Executive summary

• FY25 revenue from operations was ₹119,641.52 lakh; EBITDA reached ₹24,591.27 lakh and PAT ₹14,904.73 lakh, versus ₹101,447.45 lakh, ₹16,119.24 lakh and ₹9,049.75 lakh, respectively, in FY24.

• Management expects better results in FY26; no material changes or commitments affecting the financial position were reported between 1 April 2025 and the report date.

Financial highlights

• FY25 total income was ₹120,235.28 lakh, including other income of ₹593.76 lakh; total expenses were ₹95,644.01 lakh.

• PBT was ₹19,814.72 lakh versus ₹11,847.55 lakh; PAT increased 64.70% YoY to ₹14,904.73 lakh from ₹9,049.75 lakh.

• Total comprehensive income was ₹14,817.89 lakh versus ₹8,882.27 lakh; basic and diluted EPS were ₹24.37 versus ₹14.80.

• Net cash generated from operations was ₹19,049.42 lakh versus ₹15,676.06 lakh; investing cash outflow was ₹8,383.81 lakh versus ₹26,664.54 lakh.

Outlook and guidance

• Management expects better results in FY26; no numerical FY26 revenue or profit guidance was stated.